Enhanced antitumor effects by docetaxel/LL 37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 7291-7305

  Fan, Rangrang ^a   Tong, Aiping ^a   Li, Xiaoling ^a   Gao, Xiang ^a   Mei, Lan ^a   Zhou, Liangxue ^a   Zhang, Xiaoning ^b   You, Chao ^a   Guo, Gang ^a  

^a SICHUAN UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Coencapsulation; Hydrogel; Injectable; Intraperitoneal chemotherapy; Nanoparticles

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DOCETAXEL; NANOPARTICLE; PLURONIC L35; POLOXAMER; POLYLACTIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE; CD31 ANTIGEN; HYDROGEL; LACTIC ACID; POLYMER; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABLE IMPLANT; BODY TEMPERATURE; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMULSION; ENCAPSULATION; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CHEMISTRY; COLORECTAL NEOPLASMS; DNA FRAGMENTATION; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; NUDE MOUSE; PATHOLOGY; PERITONEAL NEOPLASMS; TEMPERATURE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATHELICIDINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA FRAGMENTATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYDROGEL; INJECTIONS, INTRAPERITONEAL; LACTIC ACID; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PERITONEAL NEOPLASMS; POLYMERS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TAXOIDS; TEMPERATURE; X-RAY DIFFRACTION;

EID: 84949883309     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S89066     Document Type: Article

References (40)

1. Ren SX, Cheng AS, To KF, et al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res. 2012;72(24):6512-6523.
2. Ren SX, Shen J, Cheng AS, et al. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One. 2013;8(5):e63641.
3. Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35(19):5226-5239.
4. Kim DH, Termsarasab U, Cho HJ, et al. Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel. Int J Nanomedicine. 2014;9:5711-5727.
5. Chu KS, Schorzman AN, Finniss MC, et al. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials. 2013;34(33):8424-8429.
6. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61(13):1203-1213.
7. Jinturkar KA, Anish C, Kumar MK, Bagchi T, Panda AK, Misra AR. Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials. 2012;33(8):2492-2507.
8. Zhou Y, Yang J, Zhang R, Kopeček J. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel. Eur J Pharm Biopharm. 2014;89:107-115.
9. Awada A, Albanell J, Canney PA, et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer. 2008;98(9):1500-1507.
10. Sun L, Zhou DS, Zhang P, Li QH, Liu P. Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma. Int J Pharm. 2014;478(1):308-317.
11. Porcelli F, Verardi R, Shi L, Henzler-Wildman KA, Ramamoorthy A, Veglia G. NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. Biochemistry. 2008;47(20):5565-5572.
12. Henzler-Wildman KA, Lee DK, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry. 2003;42(21):6545-6558.
13. Henzler-Wildman KA, Martinez GV, Brown MF, Ramamoorthy A. Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry. 2004;43(26):8459-8469.
14. Yan TD, Chu F, Links M, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol. 2006;32(10):1119-1124.
15. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev. 2008;60(15):1638-1649.
16. Shimada T, Nomura M, Yokogawa K, et al. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol. 2005;57(2):177-181.
17. Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med. 2006;354(15):1641-1643.
18. Bae WK, Park MS, Lee JH, et al. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer. Biomaterials. 2013;34(4):1433-1441.
19. Yonemura Y, Endou Y, Bando E, et al. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett. 2004;210(2):189-196.
20. Kehoe SM, Williams NL, Yakubu R, et al. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecol Oncol. 2009;113(2):228-232.
21. Nazli C, Ergenc TI, Yar Y, Acar HY, Kizilel S. RGDS-functionalized polyethylene glycol hydrogel-coated magnetic iron oxide nanoparticles enhance specific intracellular uptake by HeLa cells. Int J Nanomedicine. 2012;7:1903-1920.
22. Fan R, Deng X, Zhou L, et al. Injectable thermosensitive hydrogel composite with surface-functionalized calcium phosphate as raw materials. Int J Nanomedicine. 2014;9:615-626.
23. Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS. Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy. Int J Nanomedicine. 2012;7:4077-4088.
24. Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer. 2008;49(8):1993-2007.
25. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev. 2001;53(3):321-339.
26. Irvine DJ. Drug delivery: one nanoparticle, one kill. Nat Mater. 2011;10(5):342-343.
27. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649-1659.
28. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215-223.
29. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res. 2007;24(9):1691-1701.
30. Galaup A, Opolon P, Bouquet C, et al. Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther. 2003;7(6):731-740.
31. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
32. Lin BR, Chang CC, Chen RJ, et al. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res. 2011;17(10):3077-3088.
33. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(d,l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm. 2011;8(3):852-866.
34. Yao J, Li Y, Sun X, Dahmani FZ, Liu H, Zhou J. Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. Int J Nanomedicine. 2014;9:3313-3324.
35. Vignoni M, de Alwis Weerasekera H, Simpson MJ, et al. LL37 peptide@silver nanoparticles: combining the best of the two worlds for skin infection control. Nanoscale. 2014;6(11):5725-5728.
36. Chuang CM, Monie A, Wu A, Mao CP, Hung CF. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther. 2009;20(4):303-313.
37. An LL, Yang YH, Ma XT, et al. LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. Leuk Res. 2005;29(5):535-543.
38. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
39. Wang L, Zhang M, Zhang N, et al. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomedicine. 2011;6:2641-2652.
40. Conte C, Ungaro F, Maglio G, et al. Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer. J Control Release. 2013;167(1):40-52.